Italfarmaco S.p.A. and JCR Pharmaceuticals Co., Ltd. announced an exclusive license agreement to develop and commercialize JR-141 in the United States, Europe, and Latin America upon regulatory approval…. read more.
A short course of ultra-low-dose radiation therapy relieved painful bone lesions from multiple myeloma for most patients in a multi-institutional phase 2 clinical trial. The findings suggest that… read more.
A treatment for pain, that is delivered via a nasal spray, offers an effective, needle-free option for children being seen in the emergency department for a range of… read more.
Johnson & Johnson announced new findings on IMAAVY (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) across 15 novel abstracts to be presented at the 2026 Myasthenia… read more.
Vanda Pharmaceuticals Inc. announced positive topline results from its pivotal Phase III study of Hetlioz (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). Vanda intends… read more.
Various studies over the years have linked prenatal use of the pain reliever paracetamol (acetaminophen) with neurodevelopmental disorders such as autism and attention-deficit/hyperactivity disorder (ADHD) in children, but… read more.
AbbVie announced that the FDA has approved JUVMO (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson’s disease, a progressive… read more.
JCR Pharmaceuticals Co., Ltd. announced that the Ministry of Health, Labour and Welfare of Japan granted orphan drug designation to givinostat, an investigational drug for the treatment of… read more.
Communicating normal test results that reveal no abnormalities isn’t always enough to ease a patient’s worries. In this study, researchers asked 349 participants to imagine having gastrointestinal symptoms… read more.
“Fear and pain — together referred to as distress — are among the most common negative effects of vaccine injections,” says Dr. Anna Taddio, Leslie Dan Faculty of Pharmacy, University of… read more.
Actinogen Medical is pleased to announce that following the final trial participant visit yesterday in the USA, the Company can now confirm that topline results for the XanaMIA… read more.
Adults 65 and older with cognitive disorders such as dementia, are more likely to suffer negative effects from drugs that treat central nervous system conditions including anxiety, sleep… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
